Introduction {#s1}
============

Opioids are intensely addictive, and cessation of their chronic use is associated with a withdrawal syndrome consisting of severe early physical symptoms and late features such as craving. Relapse into drug-taking behaviors often occurs as a result of this withdrawal syndrome (Mattick and Hall, [@B23]; Williams et al., [@B35]), which is thought to result from neuronal adaptations that develop to restore homeostasis during chronic opioid exposure (Himmelsbach, [@B18]). On cessation of opioid administration, persistent counteradaptations in critical brain regions are unmasked and cause the withdrawal syndrome. A rebound increase of adenylyl cyclase/protein kinase A (PKA) signaling is one counteradaptation. While opioid agonists acutely inhibit adenylyl cyclase activity in the brain (Collier and Roy, [@B12]) and specifically in the periaqueductal gray (PAG) (Fedynyshyn and Lee, [@B15]), there is a compensatory increase in adenylyl cyclase signaling during chronic treatment with morphine *in vitro* (Sharma et al., [@B27]; Avidor-Reiss et al., [@B2]) and *in vivo* (Terwilliger et al., [@B28]) resulting in rebound hyperactivity of this cascade during withdrawal. Microinjections of PKA inhibitors into the PAG attenuate a spectrum of opioid withdrawal behaviors similar to those induced by microinjections of opioid antagonists (Maldonado et al., [@B21]; Punch et al., [@B25]). Whilst the importance of upregulated adenylyl cyclase/PKA during opioid withdrawal has been appreciated for many years we have only recently found the cellular target of PKA that results in withdrawal symptoms (Bagley et al., [@B4], [@B5]). We found that elevated PKA activity during withdrawal increases GABA transporter 1 (GAT-1) currents in PAG neurons (Bagley et al., [@B4]). Elevated GAT-1 activity directly depolarizes and thus hyperexcites GABAergic PAG neurons and nerve terminals, which presumably enhances GABAergic inhibition of PAG output neurons (Bagley et al., [@B4]). This reduced activity of PAG output neurons to several brain regions, including the hypothalamus and medulla, results in opioid withdrawal signs (Bagley et al., [@B5]).

Opioid receptors are G~i~/G~o~ coupled G-protein coupled receptors that inhibit adenylyl cyclase through their Gα subunit. The GABA~B~ receptor is another G~i~/G~o~ coupled G-protein coupled receptor (Bettler et al., [@B8]) that inhibits adenylyl cyclase activity (Gerber and Gähwiler, [@B16]; Kuner et al., [@B19]; Bettler et al., [@B8]; Vanhoose et al., [@B30]; Connelly et al., [@B13]). GABA~B~ receptors are expressed in almost all PAG neurons (Chieng and Christie, [@B11]; Margeta-Mitrovic et al., [@B22]; Bagley et al., [@B3]). The GABA~B~ receptor agonist baclofen reduces some PAG mediated signs of opioid withdrawal in humans (Ahmadi-Abhari et al., [@B1]; Tyacke et al., [@B29]) and animal models (Bexis et al., [@B9]; Tyacke et al., [@B29]) and is used in drug cocktails for treatment of opioid withdrawal (Collis, [@B11b]). Given the similarities in coupling and the therapeutic utility of GABA~B~ receptor agonists, in this study we ask whether GABA~B~ receptor agonists act like opioids to reduce GAT-1 activity during opioid withdrawal.

Materials and methods {#s2}
=====================

Chronic treatment with morphine
-------------------------------

Morphine dependence was induced by a series of subcutaneous injections of sustained-release morphine suspension into male C57B16/J mice (300 mg/kg morphine base) as in previous experiments (Bagley et al., [@B4], [@B5]). Injections (0.1--0.2 ml) were made under light halothane anesthesia on days 1, 3, and 5, and mice were used for experiments on days 6 or 7. Morphine base was suspended in 0.1 ml mannide mono-oleate (Arlacel A, Sigma), 0.4 ml light liquid paraffin and 0.5 ml 0.9% w/v NaCl in water. Vehicle-treated mice were injected on the same schedule with morphine-free suspension.

Tissue preparation and recordings
---------------------------------

PAG slices (220--250 μm) were cut from 4- to 6-week-old mice and were maintained at 34°C in a submerged chamber containing physiological saline (ACSF) equilibrated with 95% O~2~ and 5% CO~2~ and were later transferred to a chamber superfused at 2 ml/min with ACSF (34°C) for recording. The standard ACSF contained 126 mM NaCl, 2.5 mM KCl, 1.4 mM NaH~2~PO~4~, 1.2 mM MgCl~2~, 2.4 mM CaCl~2~, 11 mM glucose, and 25 mM NaHCO~3~. Brain slices from both morphine-dependent and vehicle-treated mice were maintained *in vitro* in ACSF containing 5 μM morphine. Unless otherwise stated, slices were spontaneously withdrawn by incubation in morphine-free ACSF for at least 1 h before an experiment. CGP55845 was a gift from Ciba Ltd (Basel, Switzerland).

PAG neurons were visualized using infra-red Nomarski optics. Perforated patch recordings were made using patch electrodes (4--5 mΩ) filled with 120 mM K acetate, 40 mM HEPES, 10 mM EGTA, 5 mM MgCl~2~, with 0.25 mg/ml Pluronic F-127, 0.12 mg/ml amphotericin B (pH 7.2, 290 mosmol/l). Liquid junction potentials for K acetate internal solution of −8 mV with ACSF were corrected. Series resistance (\<25 MΩ) was compensated by 80% and continuously monitored. During perforated patch recordings, currents were recorded using a Axopatch 200A amplifier (Axon Instruments), digitized, filtered (at 2 kHz), and then acquired (sampling at 10 kHz) in pClamp (Axon Instruments) or using Axograph Acquisition software (Axon Instruments).

All pooled data are expressed as mean ± s.e.m. We tested for significance using the unpaired Student\'s *t*-test.

Results {#s3}
=======

In PAG neurons, withdrawal from chronic morphine-treatment stimulates a protein kinase A-dependent increase of the GAT-1 cation conductance (Bagley et al., [@B4], [@B5]). The increased GAT-1 activity is sensitive to opioid inhibition and therefore during opioid withdrawal it can be detected by changes in the opioid agonist met-enkephalin (MENK) current reversal potential. When MENK is reducing the GAT-1 cation conductance and increasing the GIRK conductance the MENK reversal potential will be much more negative than *E*~*k*~ (Bagley et al., [@B4]). Superfusion of (MENK) produced an outward current in 4 out of 6 PAG neurons voltage clamped at −56 mV in slices from vehicle-treated mice (30 ± 4 pA, *n* = 4, Figure [1A](#F1){ref-type="fig"}). In neurons from vehicle-treated mice the ME current reversed polarity at a potential of −109 ± 4 mV (*n* = 4, Figures [1B,D](#F1){ref-type="fig"}), close to the potassium reversal potential (*E*~k~, −103 mV) in these conditions as we have previously reported in mice (Bagley et al., [@B4], [@B5]). In neurons from chronic morphine-treated mice, the MENK-induced current reversed in only 2 of 5 cells (Figure [1C](#F1){ref-type="fig"}). In the neurons where the MENK current did not reverse polarity at the most negative potential tested, the reversal potentials was assigned a value of −136 mV, a conservative approach we adopted in previous studies to deal with technical inability to determine extremely negative reversal potentials (Bagley et al., [@B4], [@B5]). The nominal reversal potential for the 5 cells was −1.8 ± 4 mV (Figures [1C,D](#F1){ref-type="fig"}) that is significantly more negative than neurons from vehicle mice (*p* = 0.034, Students *t*-test, Figure [2E](#F2){ref-type="fig"}). We have previously shown that in the presence of the GAT-1 inhibitor, NO-711, results in ME currents that reversed polarity close to the value for MENK currents in neurons from vehicle-treated mice (Bagley et al., [@B4], [@B5]).

![**Opioid receptors simultaneously couple to a potassium conductance and a GAT-1 conductance. (A)** Example trace of currents from a neuron voltage clamped at −56 mV (drug superfusion shown by bars). MENK (30 μM) induced an outward current in neuron from a morphine-treated mouse. **(B,C)** Currents produced by voltage steps from −56 mV to −136 mV in −10 mV increments in a neuron from **(B)** a vehicle-treated mouse and **(C)** a morphine-treated mouse before (left) and during MENK (30 μM) application (right). **(D)** Subtracted current-voltage relationships for MENK (current in MENK---current during control conditions). Reversal potentials were determined at the point where they cross the abscissa. The MENK current reversed polarity near *E*~K~ in neurons from vehicle-treated (*n* = 4), but not in neurons from morphine-treated mice (*n* = 5).](fphar-05-00148-g0001){#F1}

![**GABA~B~ receptors do not couple to a GAT-1 conductance. (A)** Example trace of currents from a neuron voltage clamped at −56 mV (drug superfusion shown by bars). Baclofen (10 μM) induced an outward current in a neuron from a morphine-treated mouse. **(B,C)** Currents produced by voltage steps from −56 mV to −136 mV in −10 mV increments in a neuron from **(B)** a vehicle-treated mouse and **(C)** a morphine-treated mouse before (left) and during baclofen (10 μM) application (right). **(D)** Subtracted current-voltage relationships for baclofen (current in baclofen--current during control conditions). Reversal potentials were determined at the point where they cross the abscissa. The baclofen current reversed polarity near *E*~*K*~in neurons from vehicle-treated (*n* = 8), and morphine-treated mice (*n* = 17). **(E)** Reversal potential of the MENK and baclofen-induced currents in cells from vehicle-treated and chronic morphine-treated mice. Arrows indicate that the average current did not reverse polarity at the most negative potential that could be tested (−136 mV). The number of neurons is shown beside the bar. ^\*^*P*-value of 0.034, Students *t*-test.](fphar-05-00148-g0002){#F2}

Superfusion of the GABA~B~ receptor agonist baclofen (10 μM) produced an outward current in all 8 PAG neurons voltage clamped at −56 mV in slices from vehicle-treated mice (31 ± 5 pA, *n* = 14, Figure [2A](#F2){ref-type="fig"}). In neurons from vehicle treated mice the baclofen current reversed polarity at a potential of −116 ± 5 mV (*n* = 8, Figures [2B,D,E](#F2){ref-type="fig"}), close to *E*~k~ in these conditions (−103 mV). In neurons from morphine-treated mice the baclofen-induced outward current (30 ± 5 pA, *n*= 17) reversed polarity (−117 ± 2 mV, *n* = 17, Figures [2C--E](#F2){ref-type="fig"}) close to *E*~k~ (−103 mV) and at a similar membrane potential to cells from vehicle-treated mice (*p* = 0.71 Students *t*-test).

Discussion {#s4}
==========

A cellular hallmark of withdrawal in PAG is protein kinase A-dependent increases in GAT-1 currents (Bagley et al., [@B4], [@B5]). This study showed that even though the opioid receptors and GABA~B~ receptor are both G~i~/G~o~ coupled G-proteins coupled receptors occurring in the same neurons GABA~B~ receptors are unable to couple via PKA to the additional GAT-1 conductance. The selectivity is not due to the GABA~B~ receptor and opioid receptors being located in different neurons. Whilst only two thirds to three quarters of PAG neurons are opioid sensitive, as shown in this study and previously (Vaughan et al., [@B31]), almost all PAG neurons are sensitive to GABA~B~ receptor agonists (97% in this study and Chieng and Christie, [@B11a]). In this study we only included neurons that were sensitive to both agonists. GABA~B~ receptor agonists inhibit adenylyl cyclase after expression in cell lines (Kuner et al., [@B19]; Bettler et al., [@B8]) and in brain tissue (Gerber and Gähwiler, [@B16]; Vanhoose et al., [@B30]) and there are examples where this inhibition of adenylyl cyclase regulates ionic conductances in several different brain regions (Gerber and Gähwiler, [@B16]; Connelly et al., [@B13]). Therefore, if the receptors are located on the same neurons and can couple to the adenylyl cyclase/PKA signaling pathway this suggests that there must be some sort of compartmentalization that prevents baclofen from regulating GAT-1 activity. Conversely, compartmentalization may favor opioid receptor regulation of GAT-1.

Like other G~i~/G~o~ coupled G-proteins coupled receptors GABA~B~ receptors can couple to several effectors, including calcium channels, GIRK and adenylyl cyclase. However, GABA~B~ receptors appear to show greater segregation than other G-protein coupled receptor signaling and possibly stronger regulation into nano-signaling complexes. Opioids and GABA~B~ receptors have previously been shown to differentially couple to their effectors. This occurs in GABAergic nerve terminals in the PAG. Opioid receptor activation reduces GABA release from nerve terminals in the PAG through modulation of a voltage dependent potassium channel where as GABA~B~ receptors do not couple to GABA inhibition through this mechanism (Vaughan et al., [@B32]). It seems likely that, as in this study, both the GABA~B~ receptors and opioid receptors are expressed on the same GABAergic terminals in the PAG again indicating compartmentalization. This also occurs outside the PAG. In locus coeruleus neurons both opioid and α2 receptors inhibit the same population of calcium channels in these neurons but GABA~B~ receptors inhibit a separate population of calcium channels in the same cell (Chieng and Bekkers, [@B10]). Of all the G~i~/G~o~ coupled effects there is evidence that GABA~B~ receptor regulation of AC/PKA activity may be particularly affected by compartmentalization. GABA~B~ receptor inhibition of adenylyl cyclase in the hippocampus was stimulation dependent whereas other G~i~/G~o~ coupled receptors were able to inhibit adenylyl cyclase regardless of how it was stimulated (Vanhoose et al., [@B30]). These differences may be due to GABA~B~ receptors being localized to nano-signaling complexes that influence their signaling to different effectors. The influence of nan-signaling complexes on GABA~B~ receptors on signaling is evidenced by inclusion of GABA~B~ receptors in nano-signaling complexes facilitating inhibition of calcium channels but not inhibition of adenylyl cyclase (Laviv et al., [@B20]). Further, GABA~B~ receptors, and especially the splice variants of the GABA~B1~ receptor, show differential subcellular localization and associations with protein clusters that alter their coupling to effectors (Vigot et al., [@B33]). Therefore, GABA~B~ receptors may not modulate GAT-1 activity in this study because they are preferentially associated with proteins or located in regions of the cell that do not favor inhibition of adenylyl cyclase. Whilst the evidence for strong compartmentalization of GABA~B~ receptor signaling is convincing it is also possible that it is the location/compartmentalization of the opioid receptors that allows their coupling to GAT-1 activity. Perhaps opioid receptors are more closely localized to the subcellular region or associated with the adenylyl cyclase/PKA/GAT-1 proteins upregulated by chronic opioid inhibition.

If we want to ask questions about processes occurring in the brain during particular disease states, as opposed to cell lines or cultured cells, it is critical that these experiments are conducted in native tissue. Experiments in native tissue study endogenous GPCRs with the full complement of relevant proteins and signaling molecules. In fact the opioid-AC-PKA modulation of GAT-1 was a surprise because the only consensus site for PKA phosphorylation is extracellular (Guastella et al., [@B17]) making it an unlikely candidate for regulation by PKA. Whilst the effect of PKA activation on the GAT-1 transporter has not been comprehensively studied, the subcellular location, enzymatic activity, and absolute level of GAT-1 is regulated in a complex inter-related manner by PKC activity, GABA concentration, ionic conditions, tyrosine kinase activity, and the release protein syntaxin 1A (Beckman and Quick, [@B7]; Beckman et al., [@B6]; Whitworth and Quick, [@B34]; Quick, [@B26]). Therefore, it is likely due to AC/PKA altering GAT-1 activity through an intermediary protein not expressed/or active in the cultured cells. Support for this proposal comes from another study of GAT-1 in brain tissue showing that AC/PKA activity facilitates GAT-1 transport by curbing tonic PKC-mediated inhibition of GAT-1 activity and cell surface expression (Cristóvão-Ferreira et al., [@B14]). Therefore, during opioid withdrawal the overshoot in AC/PKA activity in PAG neurons could be could indirectly increasing GAT-1 activity through reducing PKC restraints on GAT-1 activity. The results from this study also show how important it is to conduct experiments in native tissue. We would have predicted that another G~i~/G~o~ coupled GPCR, such as GABA~B~, that inhibits adenylyl cyclase (Gerber and Gähwiler, [@B16]; Kuner et al., [@B19]; Bettler et al., [@B8]; Vanhoose et al., [@B30]; Connelly et al., [@B13]) and is in the same cell as the opioid receptors would have modulated GAT-1 activity. Although GABA~B~ receptors may modulate GAT-1 activity under other conditions or in different cells it does not occur in the PAG neurons important for opioid withdrawal.

The opioid sensitive GAT-1 activity in the PAG during withdrawal initiates the opioid withdrawal syndrome (Bagley et al., [@B5]). The GABA~B~ agonist baclofen reduces some of the signs of opioid withdrawal (Ahmadi-Abhari et al., [@B1]; Bexis et al., [@B9]; Tyacke et al., [@B29]) but does not alter the GAT-1 activity. One possible explanation for this is that an important outcome of the elevated GAT-1 activity during withdrawal is depolarization of GABA neurons and a resultant increase in synaptic GABA release. The increased GABA release inhibits PAG output neurons, changes neurotransmitter release in their target brain regions and ultimately expression of the withdrawal signs. Whilst GABA~B~ receptor activation can\'t reduce the GAT-1 activity that drives GABA release it could act to inhibit the excitability of GABAergic neurons through other mechanisms. Reduced GABA release could result from inhibition of GABA neuron excitability, through activation of GIRK, and inhibition of GABA release through non-GAT1 effectors. Through this alternative mechanism of inhibiting GABA release it would diminish inhibition of output neurons and thus withdrawal.

Conflict of interest statement
------------------------------

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This study was supported by the National Health and Medical Research Council of Australia. Dr. Bagley thanks Professor M. Connor and Professor M. J. Christie for helpful discussion.

[^1]: Edited by: Dominique Massotte, Institut des Neurosciences Cellulaires et Intégratives, France

[^2]: Reviewed by: Sulev Kõks, University of Tartu, Estonia; Susan Ingram, Oregon Health & Science University, USA

[^3]: This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology.
